MétaCan
Menu
Back to cohort
Record W1967004095 · doi:10.3857/roj.2013.31.3.175

Timing of thoracic irradiation in limited stage small-cell lung cancer: is it still a star on the rise?

2013· article· en· W1967004095 on OpenAlexaboutno aff
Farkhad Manapov, Maximilian Niyazi, Minglun Li

Bibliographic record

VenueRadiation Oncology Journal · 2013
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Research Studies
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineStage (stratigraphy)Lung cancerIrradiationStar (game theory)LungCancerOncologyInternal medicineBiologyAstrophysics

Abstract

fetched live from OpenAlex

Early cisplatin-based concurrent chemoradiotherapy (CRT) is a mainstay treatment in limited stage small-cell lung cancer (LS SCLC; the Union for International Cancer Control stage I-III). This is based on the several randomized trials and meta-analyses. Most considerable of them are the National Cancer Institute of Canada (NCIC), Intergroup-0096, and the Japan Clinical Oncology Group (JCOG)-9104 trials [1-3]. These studies included pre-chemotherapy extent of the tumor in radiation portals and demonstrated 5-year survival rates over 20%. Importantly, starting point and application of thoracic irradiation (TRT) in these trials was different. In NCIC study mild hypofractionated TRT was applied with the second cycle whereas in the INT-0096 and JCOG-9104 (concurrent arm) trials accelerated hyperfractionated radiotherapy was started with the first cycle of chemotherapy. In all these trials TRT began within 30 days after initiation of chemotherapy, treatment time of TRT was less than 30 days and dose delivery of chemotherapy and TRT was more than 80%. Another substantial aspect was that deferred application of TRT in the late arms of NCIC and JCOG-9104 trials resulted in the increase of CRT duration as a whole treatment. A retrospective study has reported that in LS SCLC duration of CRT, itself, can also affect overall survival. Recently published randomized phase III trial of Sun et al. [4] demonstrated that outcome achieved with TRT starting with the third cycle of chemotherapy is non-inferior to results when radiotherapy was administered from the first day of systemic treatment. Median survival, remission rates and estimated 5-year survival rates were equal in early and late arms and comparable with best historical results. Although total radiation dose was lower than actual standard, dose-delivery of chemotherapy and TRT was high. In the late TRT arm initially involved lymph nodes were considered in the target definition even a significant response occurred after the second chemotherapy cycle. How can we declare the results of this study? Most relevant finding of Sun et al. [4] is, probably, the fact that in both arms complete responders to CRT demonstrated significant better outcome compared to partial and non-responders. Complete response remains to be highly significant variable correlating with overall survival on the multivariate analysis. This strong correlation is very important and was not reported in the earlier randomized trials. Solely, study of Jeremic et al. [5] found higher complete remission rate in the early TRT arm accompanied with better long-term results, but remission grade of the tumor, itself, was not analysed as a prognostic factor. There is a growing body of evidence to keep response of the tumor in course of CRT under control. Small studies have already demonstrated that rapid achievement of complete remission in LS SCLC can be a significant prognostic factor.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.238
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.416
Teacher spread0.358 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueRadiation Oncology JournalSame topicLung Cancer Research StudiesFrench-language works237,207